BIOMAT Database Logo BIOMAT Database Logo

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. 1985

R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim

Two selective and potent inhibitors of monoamine oxidase (MAO) type B, namely AGN-1133 (N-methyl-N-propynyl-1-indanamine) and AGN-1135 (N-propynyl-1-indanamine), given to mice prior to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) protected against the neurotoxic effects of MPTP. For example, mice treated with these agents prior to MPTP, did not exhibit the decrement in the neostriatal content of dopamine and its metabolites normally seen after MPTP administration. These data lend further support to the concept that the oxidation of MPTP by MAO-B to its corresponding pyridinium analog, 1-methyl-4-phenyl-pyridinium (MPP+) is an important feature of the neurotoxic process.

UI MeSH Term Description Entries
D007189 Indans Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES. Indanones
D007192 Indenes A family of fused-ring hydrocarbons isolated from coal tar that act as intermediates in various chemical reactions and are used in the production of coumarone-indene resins.
D008297 Male Males
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010293 Pargyline A monoamine oxidase inhibitor with antihypertensive properties. Pargyline Hydrochloride,Hydrochloride, Pargyline
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine

Related Publications

R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim
Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.
May 1981, British journal of pharmacology,
R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim
Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
July 2003, Journal of neurochemistry,
R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim
Cell death induced by MPTP, a substrate for monoamine oxidase B.
November 2000, Toxicology,
R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim
REM sleep suppression induced by selective monoamine oxidase inhibitors.
January 1982, Psychopharmacology,
R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim
Synthesis of novel MPTP analogs as potential monoamine oxidase B (MAO-B) inhibitors.
October 1992, Journal of medicinal chemistry,
R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim
Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors.
January 2018, The Canadian journal of hospital pharmacy,
R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim
Involvement of monoamine oxidase-B in the acute neurotoxicity of MPTP in embryonic and newborn mice.
May 2013, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie,
R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim
Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.
October 1992, Journal of medicinal chemistry,
R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim
Neuropharmacological studies on selective monoamine oxidase A and B inhibitors.
November 1987, Indian journal of experimental biology,
R E Heikkila, and R C Duvoisin, and J P Finberg, and M B Youdim
Design of enamides as new selective monoamine oxidase-B inhibitors.
July 2020, The Journal of pharmacy and pharmacology,
Copied contents to your clipboard!